Secondary analysis of a trial of peanut oral immunotherapy in children aged 1 to 4: consecutive missed doses during build-up (OR 0.69) and dosing reactions during maintenance (OR 0.71) were associated with lower odds of desensitisation; total missed doses were not.
Secondary analysis
Olayiwola et al. Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes